PMID- 21098416
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20181201
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 15
IP  - 4 Suppl
DP  - 2010 Dec
TI  - A review of the appropriate and inappropriate use of dronedarone: lessons learned 
      from controlled studies and regulatory submission.
PG  - 24S-30S
LID - 10.1177/1074248410368276 [doi]
AB  - Dronedarone is a multichannel blocker with electrophysiologic effects similar to 
      amiodarone. Dronedarone has been documented to prevent atrial fibrillation 
      recurrences and also has efficacy in slowing the ventricular response during 
      episodes of atrial fibrillation. However, in the ANDROMEDA trial, dronedarone was 
      associated with increased mortality when tested in New York Heart Association 
      (NYHA) III/IV patients with left ventricular ejection fractions of less than 35%, 
      who also had a recent hospitalization for decompensated heart failure. When such 
      high-risk patients with heart failure were excluded in the ATHENA trial, 
      dronedarone treatment resulted in a statistical reduction in the composite 
      primary end point of all-cause mortality or cardiovascular hospitalization. In 
      ATHENA, dronedarone reduced cardiovascular hospitalizations even though in the 
      DIONY-SOS trial dronedarone had less effect than amiodarone on suppressing atrial 
      fibrillation recurrences. The most appropriate patients for treatment with 
      dronedarone would be patients with a recent history of paroxysmal or persistent 
      atrial fibrillation/atrial flutter (AF/AFL) that have associated risk factors per 
      the inclusion criteria of ATHENA. Inappropriate patients would be those with 
      class IV heart failure or recently hospitalized for heart failure within the last 
      month from an acute decompensation, the main inclusion criteria in ANDROMEDA. 
      Dronedarone is a novel, multichannel blocking antiarrhythmic agent that may have 
      some pleiotropic effects in addition to its ability to suppress and maintain 
      sinus rhythm and control the rate during AF/AFL recurrences.
FAU - Naccarelli, Gerald V
AU  - Naccarelli GV
AD  - Heart and Vascular Institute, Penn State University College of Medicine, Hershey, 
      PA, USA. gnaccarelli@hmc.psu.edu
FAU - Wolbrette, Deborah L
AU  - Wolbrette DL
FAU - Samii, Soraya
AU  - Samii S
FAU - Banchs, Javier E
AU  - Banchs JE
FAU - Penny-Peterson, Erica
AU  - Penny-Peterson E
FAU - Gonzalez, Mario D
AU  - Gonzalez MD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Anti-Arrhythmia Agents)
RN  - JQZ1L091Y2 (Dronedarone)
RN  - N3RQ532IUT (Amiodarone)
SB  - IM
MH  - Amiodarone/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Anti-Arrhythmia Agents/administration & dosage/pharmacology/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Atrial Flutter/drug therapy
MH  - Controlled Clinical Trials as Topic
MH  - Dronedarone
MH  - Heart Failure/complications
MH  - Humans
MH  - Risk Factors
MH  - Secondary Prevention
EDAT- 2010/12/01 06:00
MHDA- 2011/03/01 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/12/01 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
AID - 1074248410368276 [pii]
AID - 10.1177/1074248410368276 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2010 Dec;15(4 Suppl):24S-30S. doi: 
      10.1177/1074248410368276.